乳腺癌
乳腺癌是一種起源于乳腺上皮細(xì)胞的惡性腫瘤,是女性中最常見的癌癥之一,也是導(dǎo)致女性癌癥死亡的主要原因之一。乳腺癌的發(fā)病率與多種因素有關(guān),包括遺傳、年齡、激素水平、生活方式等。根據(jù)腫瘤細(xì)胞的特征,乳腺癌可以分為不同的亞型,如激素受體陽性(ER+/PR+)、人表皮生長因子受體2(HER2+)和三陰性乳腺癌(TNBC)等。
近年來,乳腺癌的治療和藥物研發(fā)取得了顯著進(jìn)展。特別是在靶向治療和免疫治療領(lǐng)域,新藥物和新療法的不斷涌現(xiàn)為患者帶來了更多的治療選擇和更好的預(yù)后。
靶向治療藥物
● HER2陽性乳腺癌
HER2陽性乳腺癌的治療在過去幾年中取得了重大進(jìn)展。ADC(抗體藥物偶聯(lián)物)類藥物治療是HER2陽性乳腺癌治療的重要突破。例如,DS-8201(Trastuzumab Deruxtecan)是一種針對(duì)HER2的ADC藥物,已經(jīng)在臨床試驗(yàn)中顯示出對(duì)HER2低表達(dá)和HER2陰性乳腺癌患者的潛在療效67。此外,T-DM1(Trastuzumab Emtansine)和T-DXd(Trastuzumab Deruxtecan)也在HER2陽性乳腺癌的治療中取得了成功。
● 激素受體陽性乳腺癌
對(duì)于激素受體陽性的乳腺癌,CDK4/6抑制劑如阿貝西利(Abemaciclib)、達(dá)爾西利(Dalpiciclib)和瑞波西利(Ribociclib)等藥物的開發(fā)為患者提供了新的治療選擇。這些藥物通過抑制細(xì)胞周期的關(guān)鍵調(diào)節(jié)因子,減緩腫瘤細(xì)胞的生長和擴(kuò)散。
● 三陰性乳腺癌
三陰性乳腺癌(TNBC)是一種較為難治的亞型,因?yàn)樗狈に厥荏w和HER2的表達(dá)。然而,免疫治療在這一領(lǐng)域取得了進(jìn)展,例如PD-1/PD-L1抑制劑在TNBC的治療中顯示出潛力。
免疫治療藥物
免疫治療是乳腺癌治療領(lǐng)域的另一個(gè)重要進(jìn)展。免疫檢查點(diǎn)抑制劑,如PD-1和PD-L1抑制劑,已經(jīng)在三陰性乳腺癌的治療中顯示出一定的療效。此外,研究者正在探索將免疫治療與其他治療方法結(jié)合使用的策略,以提高治療效果。
乳腺癌藥物靶點(diǎn)
- CA9
- CD247
- CD27
- CD274
- CD276
- CD28
- CD40
- CD44
- CD47
- CEACAM5
- CSF1R
- CSF2
- CSF3R
- CTAG1A
- CTLA4
- DNA2
- EGFR
- EpCAM
- EpoR
- ERBB2
- ERBB3
- FCGR1A
- FCY1
- FGFR3
- FOLR1
- HMMR
- ICAM1
- ICOS
- IGF1
- IGF1R
- IGF2
- IL12A
- IL12RB1
- IL15RA
- IL2
- IL2RA
- IL2RB
- KDR
- LAG3
- MELTF
- MET
- MSLN
- MUC1
- MUC16
- NECTIN4
- NMT1
- NMT2
- NT5E
- PDCD1
- PRLR
- PTK7
- PVRIG
- ROR1
- SIRPA
- STING1
- TACSTD2
- TF
- TGFB1
- TGFB2
- TIGIT
- TLR8
- TNFRSF10B
- TNFRSF1A
- TNFRSF4
- TNFSF11
- TNFSF9
- TOP1
- TPBG
- VEGFA
- VSIR
- VTCN1
乳腺癌藥物靶點(diǎn)相關(guān)產(chǎn)品推薦
● 靶點(diǎn)蛋白
CSB-MP007763HU
Measured by its binding ability in a functional ELISA. Immobilized HER2 at 2 μg/ml can bind Trastuzumab, the EC50 is 2.179-2.825 ng/ml.
CSB-MP619964HU1
Measured by its binding ability in a functional ELISA. Immobilized PD-1 at 2 μg/ml can bind Anti-PD-1 recombinant antibody, the EC50 of human PD-1 protein is 6.087-7.854 ng/ml.
CSB-MP878942HU1
Measured by its binding ability in a functional ELISA. Immobilized PD-L1 at 2 μg/ml can bind Anti- PD-L1 mouse monoclonal antibody (CSB-MA878942A1m, antigen from E.coli), the EC50 of human PD-L1 protein is 1.252-1.653 ng/mL
CSB-MP023072HU1
Measured in cell activity assay using U937 cells, the EC50 for this effect is 190.2-298.6 ng/ml.
CSB-MP007765HU
Measured by its binding ability in a functional ELISA. Immobilized NRG1 (CSB-MP016077HU1(F6)) at 2 μg/ml can bind human ERBB3, the EC50 is 12.32-15.74 ng/ml.
CSB-MP006163HU1
Measured by its binding ability in a functional ELISA. Immobilized CD152 at 2 μg/ml can bind Anti-CD152 rabbit monoclonal antibody (CSB-RA213310A0HU), the EC50 of human CD152 protein is 27.14-34.82 ng/ml.
CSB-MP004940HU
Human SIRPA protein His/Myc tag (CSB-MP021334HU) captured on COOH chip can bind Human CD47 protein Fc tag (CSB-MP004940HU) with an affinity constant of 19.1 nM as detected by LSPR Assay.
CSB-MP007479HU
Human EGF protein captured on COOH chip can bind Human EGFR protein, his and Myc tag (CSB-MP007479HU) with an affinity constant of 11.9nM as detected by LSPR Assay.
● 穩(wěn)定細(xì)胞株
CT26/Human ROR1 Stable Cell Line
CSB-SC020067HU
Untransfected CT26 cells (green line) and transfected Human ROR1 CT26 stable cells (red line) were stained with anti-ROR1 antibody (CSB-RA020067A1HU) (2μg/1*106 cells), washed and then followed by FITC-conjugated anti-Human IgG Fc antibody and analyzed with flow cytometry.
● 重組抗體
CSB-RA260392A0HU
IHC image of CSB-RA260392A0HU diluted at 1:100 and staining in paraffin-embedded human breast cancer performed on a Leica BondTM system.
CSB-RA634199A0HU
IHC image of CSB-RA634199A0HU diluted at 1:100 and staining in paraffin-embedded human breast cancer performed on a Leica BondTM system.
CSB-RA292372A0HU
Overlay Peak curve showing Hela cells surface stained with CSB-RA292372A0HU (red line) at 1:50.
CSB-RA159341A0HU
Overlay histogram showing Jurkat cells stained with CSB-RA159341A0HU (red line) at 1:50.
產(chǎn)品名稱 | 貨號(hào) | 靶點(diǎn) | 反應(yīng)種屬 | 應(yīng)用范圍 |
---|---|---|---|---|
CA9 Recombinant Monoclonal Antibody | CSB-RA614990A0HU | CA9 | Human | ELISA, IHC |
CD247 Recombinant Monoclonal Antibody | CSB-RA244537A0HU | CD247 | Human | ELISA, FC |
CD27 Recombinant Monoclonal Antibody | CSB-RA953976A0HU | CD27 | Human | ELISA, WB |
CD274 Recombinant Monoclonal Antibody | CSB-RA977797A0HU | CD274 | Human | ELISA, WB, IHC |
CD274 Recombinant Monoclonal Antibody | CSB-RA878942MA1HU | CD274 | Human | ELISA, IHC, FC |
CD40 Recombinant Monoclonal Antibody | CSB-RA004936MA1HU | CD40 | Human | ELISA, IF, FC |
CD44 Recombinant Monoclonal Antibody | CSB-RA004938A0HU | CD44 | Human | ELISA, WB, IHC |
CD44 Recombinant Monoclonal Antibody | CSB-RA292372A0HU | CD44 | Human | ELISA, WB, IHC, IF, FC |
CD44 Recombinant Monoclonal Antibody | CSB-RA004938MA1HU | CD44 | Human | ELISA, FC |
CD47 Recombinant Monoclonal Antibody | CSB-RA802124A0HU | CD47 | Human | ELISA, WB, IHC, IF |
CEACAM5 Recombinant Monoclonal Antibody | CSB-RA005165MA3HU | CEACAM5 | Human | ELISA, IF, FC |
CEACAM5 Recombinant Monoclonal Antibody | CSB-RA005165MA1HU | CEACAM5 | Human | ELISA |
CTLA4 Recombinant Monoclonal Antibody | CSB-RA213310A0HU | CTLA4 | Human | ELISA, IHC |
CTLA4 Recombinant Monoclonal Antibody | CSB-RA006163MA1HU | CTLA4 | Human, Mouse | ELISA, WB, IF, FC |
Phospho-EGFR (Y1092) Recombinant Monoclonal Antibody | CSB-RA007479A1092phHU | EGFR | Human | ELISA, WB |
Phospho-EGFR (Y1068) Recombinant Monoclonal Antibody | CSB-RA007479A1068phHU | EGFR | Human | ELISA, WB |
EGFR Recombinant Monoclonal Antibody | CSB-RA159341A0HU | EGFR | Human | ELISA, WB, IHC, IF, FC |
EGFR Recombinant Monoclonal Antibody | CSB-RA794061A0HU | EGFR | Human | ELISA, WB, IHC |
EGFR Recombinant Monoclonal Antibody | CSB-RA159341MA1HU | EGFR | Human | ELISA, IHC, FC |
EPCAM Recombinant Monoclonal Antibody | CSB-RA932207A0HU | EPCAM | Human | ELISA, WB |
● ELISA試劑盒
藥物研發(fā)解決方案
特色服務(wù)項(xiàng)目
專家講堂
參考文獻(xiàn):
1. Cell 186, April 13, 2023
2. Larissa A. Korde, Mark R. Somerfield, Dawn L. Hershman, et al. Use of Immune Checkpoint Inhibitor Pembrolizumab in the Treatment of High-Risk, Early-Stage Triple-Negative Breast Cancer: ASCO Guideline Rapid Recommendation Update. DOI: 10.1200/JCO.22.00503 Journal of Clinical Oncology
3. Lajos Pusztai, Carsten Denkert, Joyce O'Shaughnessy, et al. Event-free survival by residual cancer burden after neoadjuvant pembrolizumab + chemotherapy versus placebo + chemotherapy for early TNBC: Exploratory analysis from KEYNOTE-522. J Clin Oncol 40, 2022 (suppl 16; abstr 503). DOI: 10.1200/JCO.2022.40.16_suppl.503
4. Breast cancer-WHO: https://www.who.int/news-room/fact-sheets/detail/breast-cancer